| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 411.63% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/12/2023 | 365.12% | Wedbush | → $10 | Reiterates | Outperform → Outperform |
| 07/14/2023 | 411.63% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 06/30/2023 | 365.12% | Stifel | $2 → $10 | Upgrades | Hold → Buy |
| 06/28/2023 | 411.63% | HC Wainwright & Co. | → $11 | Upgrades | Neutral → Buy |
| 06/27/2023 | -6.98% | Stifel | → $2 | Reiterates | Hold → Hold |
| 06/27/2023 | 365.12% | Wedbush | $3 → $10 | Upgrades | Neutral → Outperform |
| 05/10/2023 | 39.53% | Wedbush | → $3 | Reiterates | → Neutral |
| 03/29/2022 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 03/22/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/18/2022 | 86.05% | Stifel | $10 → $4 | Maintains | Hold |
| 09/30/2021 | 365.12% | Stifel | → $10 | Initiates Coverage On | → Hold |
| 01/07/2021 | — | Wedbush | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 2597.67% | Berenberg | → $58 | Initiates Coverage On | → Buy |
| 05/04/2020 | 2365.12% | HC Wainwright & Co. | → $53 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2086.05% | Jefferies | → $47 | Initiates Coverage On | → Buy |
| 02/24/2020 | 2225.58% | Canaccord Genuity | → $50 | Initiates Coverage On | → Buy |
| 02/24/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/24/2020 | 1853.49% | JP Morgan | → $42 | Initiates Coverage On | → Overweight |
What is the target price for Black Diamond Therapeutic (BDTX)?
The latest price target for Black Diamond Therapeutic (NASDAQ: BDTX) was reported by HC Wainwright & Co. on November 22, 2023. The analyst firm set a price target for $11.00 expecting BDTX to rise to within 12 months (a possible 411.63% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?
The latest analyst rating for Black Diamond Therapeutic (NASDAQ: BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $0.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $2.15, which is within the analyst's predicted range.